









市場
/
株式
/
nasdaq-imcr
/

Immunocore Holdings PLC

IMCR

36.130USD

-0.440-1.20%

終値 12/26, 16:00（ET）15分遅れの株価

1.80B時価総額

損失額直近12ヶ月PER



Immunocore Holdings PLC

36.130

-0.440-1.20%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Immunocore Holdings PLC 企業名

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Immunocore Holdings PLCの企業情報



企業コードIMCR

会社名Immunocore Holdings PLC

上場日Feb 05, 2021

最高経営責任者「CEO」Jallal (Bahija)

従業員数493

証券種類Depository Receipt

決算期末Feb 05

本社所在地92 Park Drive Milton Park

都市ABINGDON

証券取引所NASDAQ OMX - NASDAQ BASIC

国United Kingdom

郵便番号OX14 4RY

電話番号441235438600

ウェブサイトhttps://www.immunocore.com/

企業コードIMCR

上場日Feb 05, 2021

最高経営責任者「CEO」Jallal (Bahija)

Immunocore Holdings PLCの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

Ms. Kristine Peterson

Non-Executive Independent Director

Prof. Peter Ratcliffe

Non-Executive Independent Director

Dr. David Berman, M.D., Ph.D.

Head of Research and Development

Mr. Travis Coy

Chief Financial Officer and Head of Corporate Development

会社名

会社名/ポジション

ポジション

株式保有

変動額

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2024

FY2023

FY2023Q3

FY2023Q2

FY2022

FY2022Q3

FY2022Q2

FY2020

FY2019

会社から関連データがまだ開示されていません。

地域別USD

会社名

収益

比率

United States

226.69M

73.08%

Europe

73.22M

23.61%

International

10.08M

3.25%

Collaboration revenue

213.00K

0.07%

事業別

地域別

会社から関連データがまだ開示されていません。

株主

更新時刻: Sun, Nov 16

株主統計

種類

株主統計

比率

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

他の

50.08%

株主統計

比率

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

他の

50.08%

種類

株主統計

比率

Investment Advisor

43.18%

Hedge Fund

28.59%

Investment Advisor/Hedge Fund

24.53%

Venture Capital

1.71%

Research Firm

1.62%

Private Equity

0.77%

Pension Fund

0.56%

Bank and Trust

0.07%

Family Office

0.05%

機関投資家保有株



更新時刻: Wed, Oct 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q3

300

49.40M

99.22%

-6.80M

2025Q2

293

49.19M

99.31%

-10.02M

2025Q1

304

50.82M

102.67%

-9.36M

2024Q4

304

48.99M

99.30%

-7.33M

2024Q3

299

49.26M

99.94%

-5.38M

2024Q2

298

47.15M

96.58%

+1.62M

2024Q1

283

47.77M

97.93%

+3.51M

2023Q4

262

40.76M

86.07%

-2.70M

2023Q3

246

44.95M

95.97%

-1.86M

2023Q2

236

43.68M

94.12%

-435.38K

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

T. Rowe Price Investment Management, Inc.

7.07M

14.03%

+15.84K

+0.22%

Jun 30, 2025

RTW Investments L.P.

4.87M

9.66%

Jun 30, 2025

Wellington Management Company, LLP

5.13M

10.19%

+919.32K

+21.82%

Jul 31, 2025

Fidelity Management & Research Company LLC

4.82M

9.57%

+15.08K

+0.31%

Jun 30, 2025

PRIMECAP Management Company

3.77M

7.49%

+1.09M

+40.80%

Jun 30, 2025

Bellevue Asset Management AG

2.44M

4.85%

+1.22M

+99.86%

Jun 30, 2025

Tang Capital Management, LLC

2.11M

4.18%

+189.90K

+9.91%

Jun 30, 2025

Baker Bros. Advisors LP

2.32M

4.61%

Jun 30, 2025

Deep Track Capital LP

1.80M

3.57%

+388.60K

+27.53%

Jun 30, 2025

BVF Partners L.P.

1.02M

2.03%

+1.02M

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Immunocore Holdings PLCの上位5名の株主は誰ですか？



Immunocore Holdings PLCの上位5名の株主は以下のとおりです。
T. Rowe Price Investment Management, Inc.は7.07M株を保有しており、これは全体の14.03%に相当します。
RTW Investments L.P.は4.87M株を保有しており、これは全体の9.66%に相当します。
Wellington Management Company, LLPは5.13M株を保有しており、これは全体の10.19%に相当します。
Fidelity Management & Research Company LLCは4.82M株を保有しており、これは全体の9.57%に相当します。
PRIMECAP Management Companyは3.77M株を保有しており、これは全体の7.49%に相当します。